Diagnostic and Prognostic Potential of AKR1B10 in Human Hepatocellular Carcinoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 Apr 10

PMID 30959792

Citations 56

Authors

Johanna K DiStefano

Bethany Davis

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Although diagnostic measures and surgical interventions have improved in recent years, the five-year survival rate for patients with advanced HCC remains bleak-a reality that is largely attributable to an absence of early stage symptoms, lack of adequate diagnostic and prognostic biomarkers, and the common occurrence of acquired resistance to chemotherapeutic agents during HCC treatment. A limited understanding of the molecular mechanisms underlying HCC pathogenesis also presents a challenge for the development of specific and efficacious pharmacological strategies to treat, halt, or prevent progression to advanced stages. Over the past decade, aldo-keto reductase family 1 member 10 (AKR1B10) has emerged as a potential biomarker for the diagnosis and prognosis of HCC, and experimental studies have demonstrated roles for this enzyme in biological pathways underlying the development and progression of HCC and acquired resistance to chemotherapeutic agents used in the treatment of HCC. Here we provide an overview of studies supporting the diagnostic and prognostic utility of AKR1B10, summarize the experimental evidence linking AKR1B10 with HCC and the induction of chemoresistance, and discuss the clinical value of AKR1B10 as a potential target for HCC-directed drug development. We conclude that AKR1B10-based therapies in the clinical management of specific HCC subtypes warrant further investigation.

Citing Articles

PAXIP1 is regulated by NRF1 and is a prognosis‑related biomarker in hepatocellular carcinoma.

Cheng Q, Han X, Xie H, Liao Y, Wang F, Cui X Biomed Rep. 2025; 22(3):38.

PMID: 39781045 PMC: 11704871. DOI: 10.3892/br.2024.1916.

AKR1B10 and digestive tumors development: a review.

Shen Y, Qiu A, Huang X, Wen X, Shehzadi S, He Y Front Immunol. 2024; 15:1462174.

PMID: 39737179 PMC: 11682995. DOI: 10.3389/fimmu.2024.1462174.

STEAP4 with copper reductase activity suppresses tumorigenesis by regulating the cell cycle in hepatocellular carcinoma cells.

Yang T, Zou M, Xie Y, Zhang Y, Wang K, Jiang S Cell Div. 2024; 19(1):35.

PMID: 39719623 PMC: 11669227. DOI: 10.1186/s13008-024-00140-y.

The pan-cancer landscape of aldo-keto reductase1B10 reveals that its expression is diminished in gastric cancer.

Wu A, Li H, Gao M, Liang J, Huang J, Farres J Front Immunol. 2024; 15:1488042.

PMID: 39712017 PMC: 11659136. DOI: 10.3389/fimmu.2024.1488042.

TiRNA-Gly-GCC-002 is associated with progression in patients with hepatocellular carcinoma.

Wu L, Zhang L, Cao J, Sun Y, Zhang J, Shi L Transl Cancer Res. 2024; 13(9):4775-4785.

PMID: 39430835 PMC: 11483436. DOI: 10.21037/tcr-24-644.

References

Martin H, Breyer-Pfaff U, Wsol V, Venz S, Block S, Maser E . Purification and characterization of akr1b10 from human liver: role in carbonyl reduction of xenobiotics. Drug Metab Dispos. 2005; 34(3):464-70. DOI: 10.1124/dmd.105.007971. View

Ma J, Yan R, Zu X, Cheng J, Rao K, Liao D . Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. J Biol Chem. 2007; 283(6):3418-3423. DOI: 10.1074/jbc.M707650200. View

Gallego O, Ruiz F, Ardevol A, Dominguez M, Alvarez R, de Lera A . Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci U S A. 2007; 104(52):20764-9. PMC: 2410076. DOI: 10.1073/pnas.0705659105. View

Teramoto R, Minagawa H, Honda M, Miyazaki K, Tabuse Y, Kamijo K . Protein expression profile characteristic to hepatocellular carcinoma revealed by 2D-DIGE with supervised learning. Biochim Biophys Acta. 2008; 1784(5):764-72. DOI: 10.1016/j.bbapap.2008.02.011. View

Barski O, Tipparaju S, Bhatnagar A . The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev. 2008; 40(4):553-624. PMC: 2663408. DOI: 10.1080/03602530802431439. View

Endo S, Matsunaga T, Mamiya H, Ohta C, Soda M, Kitade Y . Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids. Arch Biochem Biophys. 2009; 487(1):1-9. DOI: 10.1016/j.abb.2009.05.009. View

Wang C, Yan R, Luo D, Watabe K, Liao D, Cao D . Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J Biol Chem. 2009; 284(39):26742-8. PMC: 2785362. DOI: 10.1074/jbc.M109.022897. View

Matsunaga T, Endo S, Soda M, Zhao H, El-Kabbani O, Tajima K . Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxycurcumin: probing the active site of the enzyme with molecular modeling and site-directed mutagenesis. Biochem Biophys Res Commun. 2009; 389(1):128-32. DOI: 10.1016/j.bbrc.2009.08.107. View

Heringlake S, Hofdmann M, Fiebeler A, Manns M, Schmiegel W, Tannapfel A . Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours. J Hepatol. 2009; 52(2):220-7. DOI: 10.1016/j.jhep.2009.11.005. View

10.

Cicinnati V, Sotiropoulos G, Beckebaum S . Established and emerging therapies for hepatocellular carcinoma. Minerva Med. 2011; 101(6):405-18. View

11.

Takemura M, Endo S, Matsunaga T, Soda M, Zhao H, El-Kabbani O . Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid. J Nat Prod. 2011; 74(5):1201-6. DOI: 10.1021/np200118q. View

12.

Zhong L, Shen H, Huang C, Jing H, Cao D . AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group. Toxicol Appl Pharmacol. 2011; 255(1):40-7. PMC: 3148280. DOI: 10.1016/j.taap.2011.05.014. View

13.

Schmitz K, Sotiropoulos G, Baba H, Schmid K, Muller D, Paul A . AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases. Liver Int. 2011; 31(6):810-6. DOI: 10.1111/j.1478-3231.2011.02511.x. View

14.

Soda M, Hu D, Endo S, Takemura M, Li J, Wada R . Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10. Eur J Med Chem. 2012; 48:321-9. DOI: 10.1016/j.ejmech.2011.12.034. View

15.

Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View

16.

Sato S, Genda T, Hirano K, Tsuzura H, Narita Y, Kanemitsu Y . Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma. Liver Int. 2012; 32(9):1382-90. PMC: 3466415. DOI: 10.1111/j.1478-3231.2012.02827.x. View

17.

Mittal S, El-Serag H . Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013; 47 Suppl:S2-6. PMC: 3683119. DOI: 10.1097/MCG.0b013e3182872f29. View

18.

Matkowskyj K, Bai H, Liao J, Zhang W, Li H, Rao S . Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions. Hum Pathol. 2014; 45(4):834-43. PMC: 4030546. DOI: 10.1016/j.humpath.2013.12.002. View

19.

Tsuzura H, Genda T, Sato S, Murata A, Kanemitsu Y, Narita Y . Expression of aldo-keto reductase family 1 member b10 in the early stages of human hepatocarcinogenesis. Int J Mol Sci. 2014; 15(4):6556-68. PMC: 4013647. DOI: 10.3390/ijms15046556. View

20.

Mounier C, Bouraoui L, Rassart E . Lipogenesis in cancer progression (review). Int J Oncol. 2014; 45(2):485-92. DOI: 10.3892/ijo.2014.2441. View